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Abstract Ovaleap (XM17) is a recombinant human folli-
cle-stimulating hormone to treat infertility by inducing
ovulation or controlled ovarian stimulation for assisted
reproductive technology (ART) procedures. Ovaleap (fol-
litropin-a) was approved by the European Medicines
Agency in 2013 as a biosimilar medicinal product to the
referencemedicine, Gonal-f. Information is often not easily
accessible and/or publicly available regarding the rigorous
manufacturing procedures for biosimilars. Objectives of the
current analysis were to report on validation procedures for
the Ovaleap manufacturing process, to compare the char-
acteristics of Ovaleap versus Gonal-f, and to describe the
performance and consistency of Ovaleap. Formal valida-
tion of the Ovaleap manufacturing process was performed
at full commercial scale, consisting of several consecutive
fermentation and purification runs. Comparison with Gonal-
f involved numerous techniques to determine molecular
structure, isoform distribution, biological activity, and pro-
duct-related impurities. The stability of the multidose
application system, targeted for long-term stability at
ambient temperature, was assessed and demonstrated. All
analyses showed the manufacturing process of Ovaleap to
be robust and consistent. Ovaleapwas found to have similar
characteristics when compared with Gonal-f. This analysis
supports the role of Ovaleap as a biosimilar to Gonal-f,
thus providing patients and clinicians with another thera-
peutic option during ART procedures.
Key Points
Comprehensive physicochemical and biological
nonclinical characterization of Ovaleap, a
recombinant human follicle-stimulating hormone to
treat infertility and an approved biosimilar,
demonstrated similar molecular characteristics and
quality attributes to the reference medicinal product,
Gonal-f.
The Ovaleap manufacturing process was found to
be robust and reliable.
The Ovaleap multidose application system was
found to have long-term stability at ambient
temperature, consistent with product labeling.
1 Introduction
Recombinant DNA methods have been frequently used to
produce proteins such as human follicle-stimulating hor-
mone (FSH) for assisted reproductive technology (ART)
procedures. Some current FSH-containing products include
those with follitropin-a (e.g. Gonal-f, Merck Serono,
Feltham, UK; Bemfola, Finox Biotech AG, Balzers,
Liechtenstein; and Pergoveris, Merck Serono, Feltham,
UK [active ingredients include both follitropin-a and
lutropin-a]) and those with follitropin-b (e.g. Puregon,
Organon, Oss, The Netherlands; Follistim, Merck Sharp
& Dohme B.V., Whitehouse Station, NJ, USA), as well as a
long-acting FSH-containing product, corifollitropin-a
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Ovaleap (XM17; Teva Pharmaceuticals Europe B.V.,
The Netherlands) is a recombinant human FSH (r-hFSH)
product that was approved in 2013 by the European
Medicines Agency (EMA) as a biosimilar medicinal pro-
duct to the reference medicine Gonal-f [1]. Ovaleap is
intended for use in women for controlled ovarian stimu-
lation and the treatment of anovulation, for stimulation of
follicular development in women with severe luteinizing
hormone (LH) and FSH deficiency (in association with an
LH preparation), and in men for spermatogenesis stimu-
lation [1]. It is supplied in cartridges (300 IU/0.5 mL/
22 lg; 450 IU/0.75 mL/33 lg; and 900 IU/1.5 mL/66 lg)
for use with a multidose reusable pen.
The active ingredient of Ovaleap (follitropin-a) is a
heterodimeric glycoprotein hormone consisting of two
subunits. The a-subunit contains 92 amino acids, 10 cys-
teine residues resulting in five disulfide bridges, and two
N-glycosylation sites, whereas the b-subunit consists of
111 amino acids, 12 cysteine residues resulting in six
disulfide bridges, and two N-glycosylation sites [1]. Each
glycosylation site might vary in terms of the composition
and complexity of the oligosaccharides attached, with
differing levels of branching, or antennary, possible (e.g.
single-branched, di-branched, tri-branched, etc.) [2].
Depending on the presence or absence of a negatively
charged sialic acid residue at the termination of each
branch, a number of different isoforms with varying iso-
electric points (pI) can exist.
Similar to most recombinant proteins, production of
r-hFSH generally follows a well-established development
process that involves (i) transfection of cultivated mam-
malian cells (e.g. Chinese Hamster Ovary [CHO] cells)
with the human FSH gene; (ii) clonal selection and isola-
tion of the production cell line; (iii) cell banking to provide
a supply of cell substrate from the selected clone for con-
tinued manufacture of the product; and (iv) large-scale
production processes involving fermentation and purifica-
tion [3]. The development of the manufacturing process
starts with pilot batches for process optimization prior to
validation and production of industrial-size, full-scale
batches with reproducible quality.
The EMA requires that biosimilar medicinal products
undergo comprehensive physicochemical and biological
nonclinical characterization, including evidence of com-
parability to the reference medicinal product [4]. The
analytical testing of Ovaleap covers two distinct aspects.
Biosimilarity testing compares molecular characteristics
and quality attributes to Gonal-f (i.e. molecular mass,
primary/secondary structure, isoform distribution, biolog-
ical activity, and impurity profile). The second analytical
testing component relates to the development of a robust
manufacturing process of Ovaleap, specifically the per-
formance and consistency of the process (i.e. final pro-
duct stability, specific activity, and batch-to-batch
variability).
Given the complexity of biosimilars compared with
conventional generics, nonclinical characterization alone is
insufficient to ensure safety and efficacy. Subtle structural
and other differences might be difficult to detect with even
the most state-of-the-art analytical techniques. Thus, even
if molecular and other analyzed characteristics are highly
similar between the biosimilar and reference product, the
bioequivalence and clinical comparability must be con-
firmed. Ovaleap has undergone several clinical studies to
demonstrate safety, tolerability, and efficacy. A phase I
clinical study assessed the safety, tolerability, and phar-
macokinetic profile of Ovaleap, whereas two clinical
comparative studies assessed bioequivalence and thera-
peutic equivalence to Gonal-f [5, 6]. The first phase I
study showed that single ascending doses of Ovaleap
exhibited dose-proportional pharmacokinetics [7]. In the
pivotal phase I, two-way, crossover study, Lammerich and
colleagues [5] demonstrated bioequivalence of single
300 IU doses of Ovaleap to Gonal-f with no serious
adverse events or adverse events leading to discontinuation
or dose reduction. Finally, in a phase III, randomized,
active-controlled study in women undergoing hyperstimu-
lation for ART, Strowitzki and colleagues [6] showed
therapeutic equivalence based on the numbers of oocytes
retrieved, with 12.2 ± 6.7 oocytes in the Ovaleap treat-
ment group compared with 12.1 ± 6.7 oocytes in the
Gonal-f group. Ovaleap and Gonal-f showed favorable
and comparable safety profiles with no unexpected safety
findings in this phase III study. In addition, the immuno-
genicity of Ovaleap was similar to that of Gonal-f [8].
Although some details regarding the manufacturing
process of biosimilar products are available only to the
EMA or other regulatory bodies and cannot be published
for proprietary reasons, other details are nonproprietary in
nature and might be of interest to the general public but are
often not published and/or not easily accessible. As such,
and given the increasing presence of biosimilar products in
the marketplace, we considered it important and timely to
report on some of the processes involved in the manufac-
turing and production of one such biosimilar product,
Ovaleap.
The objectives of the current analysis were to report on
validation procedures for the Ovaleap manufacturing
process, to compare molecular characteristics and quality
attributes of Ovaleap versus Gonal-f, and to describe the
performance and consistency of the Ovaleap manufac-
turing process.
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2 Methods
2.1 Quality Development of Ovaleap
The manufacturing process for Ovaleap takes place pri-
marily in Ulm, Germany, under full control of the manu-
facturer (Teva Biotech GmbH). As reported in the publicly
available assessment report, the manufacturing process
includes the cultivation of genetically modified CHO cells
in a serum-free cell culture medium, into which the CHO
cells secrete the active substance [1]. In order to secure
consistent product quality and long-term supply, a two-
tiered cell banking system was developed and maintained,
which consists of a master cell bank of cells from the
selected clone and a working cell bank obtained from
culturing the master cell bank. The main steps of the
Ovaleap manufacturing process include thawing of cells
and expansion in flasks, main culturing in a bioreactor,
harvesting with filtration, and purification with a series of
chromatography, virus inactivation, filtration, and ultrafil-
tration/diafiltration steps. The manufacturing process of
Ovaleap fulfilled all relevant European guidelines for
sterility and viral safety available at the time of the study
[9, 10].
2.2 Process Validation and Consistency
The formal validation of the Ovaleap manufacturing
process was performed at full commercial scale. The pro-
cess validation program consisted of several consecutive
fermentation runs and several consecutive purification
runs.
2.3 Comparability with Gonal-f
A comprehensive comparability exercise with the reference
medicinal product, Gonal-f, was performed to demon-
strate biosimilarity. Molecular mass was assessed using
various techniques, including matrix-assisted laser
desorption ionization time of flight (MALDI-TOF) mass
spectrometry and sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) with Coomassie stain.
The primary structure was evaluated with peptide mapping
using trypsin, endo Lys-C, and endo Glu-C, followed by
electrospray ionization mass spectrometry (ESI-MS)
determination of peptides. Ultraviolet spectroscopy was
used to assess the secondary structure. Isoform distribution
was determined via isoelectric focusing (IEF) and Serva
Violet 17 staining. Biological activity was determined with
several assays, including a cell-based receptor binding
assay and a rat bioassay, as requested by current EMA
guidelines [11, 12]. Product-related impurities, such as
multimers and aggregates, were assessed utilizing tech-
niques such as SDS-PAGE and size exclusion high-per-
formance liquid chromatography (SE-HPLC).
2.4 Formulation and Stability
The Ovaleap formulation was developed based on a
multidose application system targeted for long-term sta-
bility at ambient temperature. Protein stability in the final
product was assessed using a variety of storage conditions,
including long-term conditions started by a 5-day storage
period at 25 C/60% relative humidity (RH) prior to stor-
age at the claimed storage temperature of 5 C without
control of RH. These long-term conditions were performed
alone or followed by short or long temperature excursions
(Table 1).
In total, seven batches (3 9 300 IU/0.5 mL,
1 9 450 IU/0.75 mL, and 3 9 900 IU/1.5 mL), produced
at commercial scale, were included in the thermal stability
study in order to create a bracketing design. The formu-
lation of all dosage strengths is identical; only the fill
volume of the cartridges varies [i.e. 0.5 mL (300 IU),
0.75 mL (450 IU), and 1.5 mL (900 IU)]. Stability data
from the pivotal stability study of Ovaleap under condi-
tions described above were assessed for up to 24 months of
storage for all seven batches.
Table 1 Storage conditions to assess thermal stability
Storage condition Description




Storage at 25 ± 2 C/60 ± 5% RH for 5 days before storage at 5 ± 3 C, followed by a final TE at 25 ± 2 C/60 ± 5%
RH for 1 month, and 28 days broached at 25 ± 2 C/60 ± 5% RH
Long-term with long
TE
Storage at 25 ± 2 C/60 ± 5% RH for 5 days before storage at 5 ± 3 C, followed by a final TE at 25 ± 2 C/60 ± 5%
RH for 3 months, and 28 days broached at 25 ± 2 C/60 ± 5% RH
Accelerated Storage at 25 ± 2 C/65 ± 5% RH for up to 6 months
Stress Storage at 40 ± 2 C/75 ± 5% RH for up to 3 months
TE temperature excursion, RH relative humidity
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Additionally, accelerated and stress storage conditions
(up to 6 and 3 months, respectively) were investigated to
provide supporting data on product stability, as recom-
mended by the relevant guidelines [13], but will not be the
focus of this report.
A filled-by-mass approach was used for filling cartridges
(follitropin-a, 44 lg/mL). Batch-to-batch variability was
assessed.
3 Results
3.1 Process Validation and Consistency
In the Ovaleap fermentation process, all analyzed batch
samples demonstrated that the manufacturing process is
robust. The characteristics of all validation runs of inter-
mediate cultures and main cultures in the production
bioreactor were consistent and comparable.
The purification process, as measured by step recovery
and yield, allowed for consistent and reproducible manu-
facturing of Ovaleap. The r-hFSH produced in this pro-
cess passed all in-process and release specifications in all
validation runs. The consistency of the Ovaleap purifi-
cation process was demonstrated by highly comparable
chromatogram profiles, reproducible elution positions of
product, and removal of contaminants from chromato-
graphic steps. The hygiene status of the overall purification
process was well-controlled, as is shown by the absence of
bioburden and endotoxin in the product intermediates and
purified bulks of all validation batches.
3.2 Comparability with Gonal-f
A summary of the results of the extensive program for
characterization of Ovaleap and comparability with
Gonal-f is shown in Table 2. Structural characteristics
and product-related impurities were similar between
Ovaleap and Gonal-f, and no substantive differences
were found with respect to molecular mass, primary
structure, secondary structure, biological activity, and
product-related impurities.
The pattern of isoform distribution as analyzed by IEF
was comparable between different batches of Ovaleap
consistent with high batch-to-batch consistency (Fig. 1). In
addition, the batches of Ovaleap show a very similar
distribution pattern of charged isoforms to those of Gonal-
f. Nine isoforms were detectable with pI values between
3.5 and 5.3 for both Ovaleap and Gonal-f. As charge
differences mainly derive from differentially glycosylated
follitropin, these results do not give any indication that
there are relevant physicochemical differences between
Ovaleap and Gonal-f.
3.3 Formulation and Stability
The active substance is formulated with sodium dihydro-
gen phosphate dihydrate (buffer), sodium hydroxide (pH-
adjusting agent), mannitol (tonicity-adjusting agent), L-
methionine (antioxidant), polysorbate 20 (solubilizer),
benzyl alcohol (preservative—multidose preparation),
benzalkonium chloride (preservative—multidose prepara-
tion) and water for injection (vehicle). These excipients are
commonly used for biopharmaceutical preparations.
The developed formulation resulted in high protein
stability. Data on storage for up to 24 months under long-
term conditions alone and under long-term conditions
with either long or short temperature excursions were
within the specified ranges. Ovaleap oxidized by RP-
HPLC resulted in values between\1.0 and 1.4% for all
seven batches when stored over 24 months at 2–8 C
(Fig. 2). Similarly, results of Ovaleap monomer/aggre-
gates by SE-HPLC for all seven batches indicated 100%
monomers and no aggregates, and these results were
constant over 24 months of storage at 25 C. No trend
was observed, therefore no statistical evaluation was
applicable and all values were within Ovaleap
specification.
Eight commercial batches were examined for protein
content (batch numbers 808064, 809064, 7064, 8064,
102074, 103074, 198074, 199074). Filling by mass led to
consistent dosage strength with very low batch-to-batch
variability (Fig. 3).
4 Discussion
Ovaleap, approved by the EMA in 2013 as a biosimilar to
Gonal-f, is produced via a robust and safe manufacturing
process completely under the control of the manufacturer.
Ovaleap is manufactured using a CHO cell line, an
extensively studied and widely utilized cell line for bio-
pharmaceutical manufacturing processes with mammalian
cell culture technology. The cell line and process, which
includes a state-of-the-art, serum-free cell culture media,
adhere to all relevant guidelines regarding viral safety in
order to exclude any viral or prion contamination.
In the current analysis, the process validation studies
effectively demonstrated that the fermentation and purifi-
cation processes are consistent and reproducible in deliv-
ering high-quality, intermediate, and purified bulk
Ovaleap product. Results of the extended characterization
program comparing Ovaleap with Gonal-f were as
expected. Ovaleap was shown to have a high degree of
similarity to Gonal-f with respect to molecular mass,
primary structure, secondary structure, isoform distribu-
tion, biological activity, and product-related impurities.
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In terms of product stability, no change in quality or
consistency was observed when Ovaleap was stored for
up to 24 months at 5 ± 3 C in multidose cartridges, rep-
resenting the primary form of packaging. Additionally,
data obtained during storage under long-term conditions
with both long and short temperature excursions
(?3 months at 25 C ?28 days broached at 25 C, and
?1 month at 25 C ?28 days broached at 25 C, respec-
tively) prior to removal from storage provided evidence
that the quality of Ovaleap would not be adversely
affected by storage at 25 C for 1–3 months (?28 days
broached at 25 C). Therefore, a shelf-life of 24 months
while stored at 2–8 C was supported by the available data.
Furthermore, commercial batches show consistent dosage
strength with very low batch-to-batch variability.
The formulation of Ovaleap was developed based on a
multidose application system. Ovaleap is presented as a
sterile, clear solution for subcutaneous injection at the
concentration of 600 IU/44 lg follitropin-a per mL. The
Ovaleap cartridge can be stored for up to 3 months at
room temperature (B25 C) and for up to an additional
28 days at room temperature (B25 C) once in the pen.
Benefits of the Ovaleap pen device include reusability,
compatibility with all three dosing cartridges (300, 450,
Table 2 Overview of extended characterization program of Ovaleap and comparability with Gonal-f





Nonreduced SDS-PAGE Coomassie staining Main band with approximately 40 kDa Main band with approximately 40 kDa
Reduced Main band with approximately
20 kDa; additional faint bands
between 16 and 20 kDa
Main band with approximately
20 kDa; additional faint bands
between 16 and 20 kDa
a-Subunit
(native)
MALDI-TOF MS 14.6 kDa 14.6 kDa
b-Subunit
(native)
17.8/18.3 kDaa 17.8/18.3 kDaa
Primary structure
Peptide mapping Peptide mapping using trypsin,
endo Lys-C, and endo Glu-C
followed by ESI-MS
determination of peptides
All determined masses of peptides
correspond with expected masses;
100% sequence coverage achieved
All determined masses of peptides
correspond with expected masses;
100% sequence coverage achieved
Similar peptide maps obtained with Ovaleap and Gonal-f
Secondary structure
Structural topology Far-UV circular dichroism
spectroscopy
Samples have identical structural
conformations and folding, which
are superimposable with those of
FSH reference standard
Samples have identical structural
conformations and folding, which





Isoelectric focusing (Serva Violet
17 staining)
Nine isoforms detectable with pI
values between 3.6 and 5.3
Nine isoforms detectable with pI
values between 3.6 and 5.3
High similarity with respect to isoform distribution between Ovaleap and
Gonal-f
Biological activity
In vitro bioassay Cell-based receptor binding assay Similar specific activities and dose–response curves obtained for Ovaleap and
Gonal-f





SE-HPLC No aggregates detectable No aggregates detectable
Nonreducing SDS-PAGE
Western immunoblot
No aggregates detectable; expected
main band of heterodimer, additional
faint bands of free subunits
No aggregates detectable; expected
main band of heterodimer, additional





No truncated forms detectable;
expected bands of free subunits
No truncated forms detectable;
expected bands of free subunits
ESI-MS electrospray ionization mass spectrometry, FSH follicle-stimulating hormone, kDa kilodalton, MALDI-TOF MS matrix-assisted laser
desorption ionization time of flight mass spectrometry, pI isoelectric points, r-hFSH recombinant human FSH, SDS-PAGE sodium dodecyl
sulfate polyacrylamide gel electrophoresis, SE-HPLC size exclusion high-performance liquid chromatography, UV ultraviolet
a After harsh denaturation and reducing conditions
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and 900 IU), flexible dosing (12.5 IU dosing increments),
reduced residual medication, easy changing of cartridges,
and an environmentally friendly package. Other attributes
of the pen device include the dial-back function, which
allows for correction in case of over-rotation for dosing;
the large window, which allows for easy reading of the























AFig. 1 Isoform distribution of
Ovaleap versus Gonal-f by
isoelectric focusing, as shown
by a bar graph and b gel (Serva
Violet 17 stain). In b, the
decimal place is represented by
a comma. Lane assignments are
as follows: lanes 1 and 2 Gonal-
f; lane 3 pI marker; lane 4







































Fig. 2 Summary of RP-HPLC
results for oxidized Ovaleap
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dose to be displayed; the clear cartridge housing, which
allows for quick confirmation of medication in the car-
tridge; and the release button on the side of the pen, which
allows for an automatic release of the entire dose after
touching this button (semi-automatic) for ease of use and
comfort.
5 Conclusions
The current physicochemical and biological nonclinical
analysis demonstrates the robust and rigorous nature of the
Ovaleap manufacturing process. The study confirms the
reproducible quality of Ovaleap and the high similarity to
Gonal-f on a molecular/physicochemical level. Due to the
complexity of biosimilar products such as Ovaleap, an
heterodimeric glycoprotein composed of 92 amino acids in
the a-subunit and 111 amino acids in the b-subunit, even
state-of-the-art analytical techniques might be insufficient
to detect subtle differences compared with the reference
product. The results of these comparative nonclinical
analyses are further supported by a clinical development
program, including a pharmacokinetic bioequivalence and
a clinical comparability study, which have shown bioe-
quivalence and therapeutic equivalence of Ovaleap
compared with Gonal-f [5, 6]. As a product biosimilar to
Gonal-f, Ovaleap provides consumers and clinicians
with an additional option when planning for ART
procedures.
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